TY - JOUR
T1 - Impact of diabetes mellitus on the outcome of pancreatic cancer
AU - Beg, Muhammad Shaalan
AU - Dwivedi, Alok Kumar
AU - Ahmad, Syed Arif
AU - Ali, Sadia
AU - Olowokure, Olugbenga
PY - 2014/5/30
Y1 - 2014/5/30
N2 - Introduction: Diabetes mellitus (DM) has the potential to impact the pathogenesis, treatment, and outcome of pancreatic cancer. This study evaluates the impact of DM on pancreatic cancer survival. Methods: We conducted a retrospective cohort study from the Veterans Affairs (VA) Central Cancer Registry (VACCR) for pancreatic cancer cases between 1995 and 2008. DM and no-DM cases were identified from comorbidity data. Univariate and multivariable analysis was performed. Multiple imputation method was employed to account for missing variables. Results: Of 8,466 cases of pancreatic cancer DM status was known in 4728 cases that comprised this analysis. Males accounted for 97.7% cases, and 78% were white. Overall survival was 4.2 months in DM group and 3.6 months in the no-DM group. In multivariable analysis, DM had a HR = 0.91 (0.849-0.974). This finding persisted after accounting for missing variables using multiple imputations method with the HR in DM group of 0.93 (0.867-0.997). Conclusions: Our data suggest DM is associated with a reduction in risk of death in pancreatic cancer. Future studies should be directed towards examining this association, specifically impact of DM medications on cancer outcome.
AB - Introduction: Diabetes mellitus (DM) has the potential to impact the pathogenesis, treatment, and outcome of pancreatic cancer. This study evaluates the impact of DM on pancreatic cancer survival. Methods: We conducted a retrospective cohort study from the Veterans Affairs (VA) Central Cancer Registry (VACCR) for pancreatic cancer cases between 1995 and 2008. DM and no-DM cases were identified from comorbidity data. Univariate and multivariable analysis was performed. Multiple imputation method was employed to account for missing variables. Results: Of 8,466 cases of pancreatic cancer DM status was known in 4728 cases that comprised this analysis. Males accounted for 97.7% cases, and 78% were white. Overall survival was 4.2 months in DM group and 3.6 months in the no-DM group. In multivariable analysis, DM had a HR = 0.91 (0.849-0.974). This finding persisted after accounting for missing variables using multiple imputations method with the HR in DM group of 0.93 (0.867-0.997). Conclusions: Our data suggest DM is associated with a reduction in risk of death in pancreatic cancer. Future studies should be directed towards examining this association, specifically impact of DM medications on cancer outcome.
UR - http://www.scopus.com/inward/record.url?scp=84902340045&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84902340045&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0098511
DO - 10.1371/journal.pone.0098511
M3 - Article
C2 - 24879130
AN - SCOPUS:84902340045
SN - 1932-6203
VL - 9
JO - PloS one
JF - PloS one
IS - 5
M1 - e98511
ER -